FNA - Paragon 28, Inc. Stock Price, Fair Value and News

7.65USD-0.32 (-4.02%)Delayed

Market Summary

USD7.65-0.32

Delayed

-4.02%

FNA Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

FNA Stock Price

View Fullscreen

FNA RSI Chart

FNA Valuation

Market Cap

634.6M

Price/Earnings (Trailing)

-11.75

Price/Sales (Trailing)

2.81

EV/EBITDA

-22.68

Price/Free Cashflow

-10.43

FNA Price/Sales (Trailing)

FNA Profitability

Operating Margin

79.21%

EBT Margin

-23.74%

Return on Equity

-32.85%

Return on Assets

-16.15%

Free Cashflow Yield

-9.58%

FNA Fundamentals

FNA Revenue

Revenue (TTM)

225.4M

Rev. Growth (Yr)

17.38%

Rev. Growth (Qtr)

0.86%

FNA Earnings

Earnings (TTM)

-54.0M

Earnings Growth (Yr)

-68.29%

Earnings Growth (Qtr)

22.11%

Breaking Down FNA Revenue

Last 7 days

-1.3%

Last 30 days

-21.4%

Last 90 days

-45.1%

Trailing 12 Months

-58.6%

How does FNA drawdown profile look like?

FNA Financial Health

Current Ratio

3.57

Debt/Equity

0.67

Debt/Cashflow

-0.55

FNA Investor Care

Shares Dilution (1Y)

0.77%

Diluted EPS (TTM)

-0.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	225.4M	0	0	0
2023	192.0M	200.6M	207.3M	216.4M
2022	155.7M	162.5M	172.7M	181.4M
2021	120.1M	129.2M	138.3M	147.5M
2020	0	0	108.6M	111.0M
2019	0	0	0	106.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Paragon 28, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	dacosta albert	bought	255,226	9.1152	28,000	see remarks
Mar 08, 2024	dacosta albert	acquired	-	-	166,924	see remarks
Mar 08, 2024	deitsch stephen	acquired	-	-	108,346	chief financial officer
Mar 08, 2024	mickelson erik e	acquired	-	-	15,455	chief accounting officer
Mar 08, 2024	mccormack robert s	acquired	-	-	71,483	see remarks
Mar 08, 2024	jarboe matthew	acquired	-	-	98,454	chief commercial officer
Feb 28, 2024	mickelson erik e	sold (taxes)	-11,226	12.15	-924	chief accounting officer
Feb 28, 2024	jarboe matthew	sold (taxes)	-39,876	12.15	-3,282	chief commercial officer
Feb 28, 2024	deitsch stephen	sold (taxes)	-43,897	12.15	-3,613	chief financial officer
Feb 28, 2024	dacosta albert	sold (taxes)	-115,060	12.15	-9,470	see remarks

Which funds bought or sold FNA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	sold off	-100	-273	-	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-79.07	-887,270	232,946	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	3.35	12,235	467,645	-%
May 15, 2024	MORGAN STANLEY	reduced	-11.21	-332,791	2,490,980	-%
May 15, 2024	OCCUDO QUANTITATIVE STRATEGIES LP	added	135	213,802	373,279	0.06%
May 15, 2024	Woodline Partners LP	reduced	-71.09	-4,434,120	1,786,750	0.02%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	new	-	853	853	-%
May 15, 2024	Voya Investment Management LLC	reduced	-19.09	-44,092	180,779	-%
May 15, 2024	UBS ASSET MANAGEMENT AMERICAS LLC	reduced	-1.44	-10,289	484,885	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-3.08	-338,248	8,785,000	-%

Are Funds Buying or Selling FNA?

Are funds buying FNA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FNA

No. of Funds

Unveiling Paragon 28, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	dacosta albert	14.2%	11,832,644	SC 13G/A
Feb 13, 2024	mvm partners, llc	13.2%	10,886,145	SC 13G/A
Feb 14, 2023	mvm partners, llc	17.7%	13,659,625	SC 13G/A
Feb 13, 2023	rosenthal investment company, llc	9.4%	7,214,165	SC 13G/A
Feb 13, 2023	dacosta albert	16.6%	12,782,924	SC 13G/A
Jan 12, 2023	bird b. ag	20.2%	15,551,180	SC 13G
Jul 29, 2022	rosenthal investment company, llc	9.4%	7,214,165	SC 13G
Feb 11, 2022	dacosta albert	15.9%	12,238,500	SC 13G
Feb 09, 2022	mvm partners llp	18.9%	14,414,195	SC 13G

Recent SEC filings of Paragon 28, Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	DEFA14A	DEFA14A
Apr 04, 2024	8-K	Current Report
Mar 18, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	3	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading

Peers (Alternatives to Paragon 28, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Paragon 28, Inc. News

Latest updates

Paragon 28, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Revenue	0.9%	61,082,000	60,561,000	52,783,000	51,009,000	52,036,000	51,508,000	46,006,000	42,498,000	41,371,000	42,775,000	35,851,000	35,734,000	33,104,000	31,686,000	30,268,000	-
Cost Of Revenue	-21.1%	12,186,000	15,440,000	10,394,000	8,858,000	8,906,000	9,537,000	8,491,000	7,638,000	6,791,000	7,815,000	7,096,000	6,672,000	6,441,000	-	7,049,000	-
Gross Profit	8.4%	48,896,000	45,121,000	42,389,000	42,151,000	43,130,000	41,971,000	37,515,000	34,860,000	34,580,000	34,960,000	28,755,000	29,062,000	26,663,000	-	23,219,000	-
Operating Expenses	9.7%	61,799,000	56,351,000	51,370,000	51,510,000	50,869,000	78,016,000	46,004,000	43,938,000	43,015,000	39,952,000	33,086,000	30,232,000	26,945,000	-	19,304,000	-
S&GA Expenses	12.4%	54,215,000	48,249,000	44,126,000	43,827,000	43,820,000	44,466,000	39,667,000	37,948,000	37,242,000	35,078,000	28,968,000	26,645,000	23,396,000	-	16,958,000	-
R&D Expenses	-6.4%	7,584,000	8,102,000	7,244,000	7,683,000	7,049,000	6,550,000	6,337,000	5,990,000	5,773,000	4,874,000	4,118,000	3,587,000	3,549,000	-	2,346,000	-
EBITDA Margin	-7.9%	-0.13	-0.12	-0.23	-0.25	-0.25	-0.27	-0.11	-0.09	-0.06	-0.02	0.09	0.09	0.10	0.11	-	-
Interest Expenses	28.7%	2,622,000	2,038,000	1,119,000	803,000	1,205,000	1,264,000	1,093,000	1,104,000	668,000	545,000	573,000	537,000	64,000	-	70,000	-
Income Taxes	82.1%	224,000	123,000	-108,000	269,000	-71,000	-370,000	201,000	73,000	32,000	276,000	105,000	178,000	154,000	-	-19,000	-
Earnings Before Taxes	22.8%	-15,010,000	-19,436,000	-8,440,000	-10,629,000	-9,123,000	-39,133,000	-9,523,000	-9,530,000	-9,204,000	-5,899,000	-5,002,000	-1,706,000	-373,000	-	3,789,000	-
EBT Margin	-7.9%	-0.24	-0.22	-0.32	-0.34	-0.35	-0.37	-0.20	-0.18	-0.14	-0.09	0.04	0.04	0.04	0.05	-	-
Net Income	22.1%	-15,234,000	-19,559,000	-8,332,000	-10,898,000	-9,052,000	-38,763,000	-9,724,000	-9,603,000	-9,236,000	-6,175,000	-5,107,000	-1,884,000	-527,000	-	3,808,000	-
Net Income Margin	-8.4%	-0.24	-0.22	-0.32	-0.34	-0.35	-0.37	-0.20	-0.19	-0.14	-0.09	0.03	0.03	0.03	0.03	-	-
Free Cashflow	32.9%	-10,993,000	-16,373,000	-21,947,000	-27,176,000	-21,581,000	-19,399,000	-18,279,000	-39,510,000	-13,533,000	-10,147,000	-8,815,000	-3,304,000	653,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4	2020Q3
Assets	-1.8%	335	341	293	301	314	254	257	265	269	235	122	98.00	98.00
Current Assets	-3.9%	207	216	169	180	197	142	150	161	169	180	72.00	72.00	-
Cash Equivalents	-23.0%	58.00	76.00	35.00	57.00	86.00	38.00	56.00	73.00	94.00	109	8.00	18.00	18.00
Inventory	6.4%	104	98.00	94.00	85.00	69.00	61.00	55.00	52.00	43.00	40.00	38.00	32.00	-
Net PPE	2.1%	76.00	74.00	74.00	71.00	67.00	62.00	59.00	56.00	52.00	32.00	26.00	22.00	-
Goodwill	0%	25.00	25.00	25.00	25.00	25.00	25.00	27.00	27.00	27.00	19.00	7.00	-	-
Liabilities	4.4%	170	163	100	102	108	113	86.00	88.00	84.00	42.00	55.00	26.00	-
Current Liabilities	13.3%	58.00	51.00	55.00	56.00	64.00	69.00	42.00	44.00	38.00	34.00	29.00	22.00	-
Long Term Debt	0.0%	110	110	42.00	42.00	42.00	42.00	42.00	43.00	42.00	7.00	23.00	4.00	-
LT Debt, Current	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	2.00	-
LT Debt, Non Current	-100.0%	-	110	42.00	42.00	42.00	42.00	42.00	43.00	42.00	7.00	23.00	4.00	-
Shareholder's Equity	-7.5%	164	178	194	199	205	141	171	177	185	192	24.00	30.00	24.00
Retained Earnings	-13.2%	-130	-115	-96.07	-87.74	-76.84	-67.79	-29.03	-19.30	-9.70	-0.46	3.00	12.00	-
Additional Paid-In Capital	1.0%	301	298	296	292	287	214	207	202	200	198	26.00	22.00	-
Shares Outstanding	0.1%	83.00	83.00	83.00	83.00	82.00	78.00	77.00	76.00	76.00	53.00	47.00	-	-
Float	-	-	-	-	831	-	-	-	521	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	32.9%	-10,993	-16,373	-14,114	-19,343	-14,060	-13,231	-12,111	-33,342	9,503	-2,121	-5,062	180	3,686	-	-	-
Share Based Compensation	49.2%	3,088	2,070	3,512	3,600	3,182	3,313	2,587	2,343	2,122	2,201	1,032	857	858	-	-	-
Cashflow From Investing	-16.6%	-5,778	-4,956	-6,768	-7,711	-7,552	-7,174	-5,547	-6,336	-41,636	-9,605	-3,911	-18,959	-3,015	-	-	-
Cashflow From Financing	-102.0%	-1,262	63,173	-1,351	-2,536	69,367	2,550	1,220	147	35,570	113,300	1,083	16,735	-22.00	-	-	-
Buy Backs	-	-	-	-	-	-	-	-	266	-	-	-	-	561	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FNA Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net revenue	$ 61,082	$ 52,036
Cost of goods sold	12,186	8,906
Gross profit	48,896	43,130
Operating expenses
Research and development costs	7,584	7,049
Selling, general, and administrative	54,215	43,820
Total operating expenses	61,799	50,869
Operating loss	(12,903)	(7,739)
Other income (expense):
Other income (expense), net	515	(179)
Interest expense, net	(2,622)	(1,205)
Total other expense, net	(2,107)	(1,384)
Loss before income taxes	(15,010)	(9,123)
Income tax expense (benefit)	224	(71)
Net loss	(15,234)	(9,052)
Foreign currency translation adjustment	(1,097)	(99)
Comprehensive loss	$ (16,331)	$ (9,151)
Weighted average number of shares of common stock outstanding:
Basic	82,854,334	80,681,715
Diluted	82,854,334	80,681,715
Net loss per share attributable to common stockholders:
Basic	$ (0.18)	$ (0.11)
Diluted	$ (0.18)	$ (0.11)

FNA Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 58,222	$ 75,639
Trade receivables, net of allowance for doubtful accounts of $1,701 and $1,339, respectively	40,262	37,323
Inventories, net	104,298	98,062
Income taxes receivable	597	794
Other current assets	4,013	3,997
Total current assets	207,392	215,815
Property and equipment, net	75,701	74,122
Intangible assets, net	21,458	21,674
Goodwill	25,465	25,465
Deferred income taxes	678	705
Other assets	3,900	2,918
Total assets	334,594	340,699
Current liabilities:
Accounts payable	29,224	21,696
Accrued expenses	26,823	27,781
Other current liabilities	909	883
Current maturities of long-term debt	640	640
Income taxes payable	450	243
Total current liabilities	58,046	51,243
Long-term liabilities:
Long-term debt net, less current maturities	109,847	109,799
Other long-term liabilities	1,356	1,048
Deferred income taxes	231	233
Income taxes payable	638	635
Total liabilities	170,118	162,958
Commitments and contingencies (Note 10)
Stockholders' equity:
Common stock, $0.01 par value, 300,000,000 shares authorized; 83,858,930 and 83,738,974 shares issued, and 82,945,411 and 82,825,455 shares outstanding as of March 31, 2024 and December 31, 2023, respectively	828	827
Additional paid in capital	301,459	298,394
Accumulated deficit	(130,864)	(115,630)
Accumulated other comprehensive loss	(965)	132
Treasury stock, at cost; 913,519 shares as of March 31, 2024 and December 31, 2023	(5,982)	(5,982)
Total stockholders' equity	164,476	177,741
Total liabilities & stockholders' equity	$ 334,594	$ 340,699

About Paragon 28, Inc.

Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

CEO	Mr. Albert DaCosta
WEBSITE	paragon28.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	463

Paragon 28, Inc. Frequently Asked Questions

What is the ticker symbol for Paragon 28, Inc.? What does FNA stand for in stocks?

FNA is the stock ticker symbol of Paragon 28, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Paragon 28, Inc. (FNA)?

As of Fri May 17 2024, market cap of Paragon 28, Inc. is 634.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FNA stock?

You can check FNA's fair value in chart for subscribers.

What is the fair value of FNA stock?

You can check FNA's fair value in chart for subscribers. The fair value of Paragon 28, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Paragon 28, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Paragon 28, Inc. a good stock to buy?

The fair value guage provides a quick view whether FNA is over valued or under valued. Whether Paragon 28, Inc. is cheap or expensive depends on the assumptions which impact Paragon 28, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FNA.

What is Paragon 28, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, FNA's PE ratio (Price to Earnings) is -11.75 and Price to Sales (PS) ratio is 2.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FNA PE ratio will change depending on the future growth rate expectations of investors.